Literature DB >> 19374929

Influenza vaccines based on virus-like particles.

Sang-Moo Kang1, Jae-Min Song, Fu-Shi Quan, Richard W Compans.   

Abstract

The simultaneous expression of structural proteins of virus can produce virus-like particles (VLPs) by a self-assembly process in a viral life cycle even in the absence of genomic material. Taking an advantage of structural and morphological similarities of VLPs to native virions, VLPs have been suggested as a promising platform for new viral vaccines. In the light of a pandemic threat, influenza VLPs have been recently developed as a new generation of non-egg based cell culture-derived vaccine candidates against influenza infection. Animals vaccinated with VLPs containing hemagglutinin (HA) or HA and neuraminidase (NA) were protected from morbidity and mortality resulting from lethal influenza infections. Influenza VLPs serve as an excellent model system of an enveloped virus for understanding the properties of VLPs in inducing protective immunity. In this review, we briefly describe the characteristics of influenza VLPs assembled with a lipid bilayer containing glycoproteins, and summarize the current progress on influenza VLPs as an alternative vaccine candidate against seasonal as well as pandemic influenza viruses. In addition, the protective immune correlates induced by vaccination with influenza VLPs are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374929      PMCID: PMC2753524          DOI: 10.1016/j.virusres.2009.04.005

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  69 in total

1.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Safety, immunogenicity and efficacy of influenza vaccine in children.

Authors:  Otávio A L Cintra; Luis C Rey
Journal:  J Pediatr (Rio J)       Date:  2006-06-21       Impact factor: 2.197

3.  Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

Authors:  Peter Pushko; Terrence M Tumpey; Fang Bu; John Knell; Robin Robinson; Gale Smith
Journal:  Vaccine       Date:  2005-08-15       Impact factor: 3.641

4.  Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model.

Authors:  Aleksandr S Lipatov; Richard J Webby; Elena A Govorkova; Scott Krauss; Robert G Webster
Journal:  J Infect Dis       Date:  2005-03-14       Impact factor: 5.226

5.  Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.

Authors:  Jose M Galarza; Theresa Latham; Albert Cupo
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

Review 6.  Human papillomavirus vaccines.

Authors:  Margaret A Stanley
Journal:  Rev Med Virol       Date:  2006 May-Jun       Impact factor: 6.989

7.  Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies.

Authors:  Ling Ye; Jianguo Lin; Yuliang Sun; Soumaya Bennouna; Michael Lo; Qingyang Wu; Zhigao Bu; Bali Pulendran; Richard W Compans; Chinglai Yang
Journal:  Virology       Date:  2006-05-04       Impact factor: 3.616

8.  Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls.

Authors:  Ron A M Fouchier; Vincent Munster; Anders Wallensten; Theo M Bestebroer; Sander Herfst; Derek Smith; Guus F Rimmelzwaan; Björn Olsen; Albert D M E Osterhaus
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses.

Authors:  Judit Szécsi; Bertrand Boson; Per Johnsson; Pia Dupeyrot-Lacas; Mikhail Matrosovich; Hans-Dieter Klenk; David Klatzmann; Viktor Volchkov; François-Loïc Cosset
Journal:  Virol J       Date:  2006-09-03       Impact factor: 4.099

Review 10.  Assembly and budding of influenza virus.

Authors:  Debi P Nayak; Eric Ka-Wai Hui; Subrata Barman
Journal:  Virus Res       Date:  2004-12       Impact factor: 3.303

View more
  54 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Authors:  Fu-Shi Quan; Yonghwan Kim; Sujin Lee; Hong Yi; Sang-Moo Kang; Jadranka Bozja; Martin L Moore; Richard W Compans
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

3.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

Review 4.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

Review 5.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

6.  Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.

Authors:  M Jaber Hossain; Melissa Bourgeois; Fu-Shi Quan; Aleksandr S Lipatov; Jae-Min Song; Li-Mei Chen; Richard W Compans; Ian York; Sang-Moo Kang; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2011-10-26

Review 7.  Cutaneous immunization: an evolving paradigm in influenza vaccines.

Authors:  Harvinder S Gill; Sang-Moo Kang; Fu-Shi Quan; Richard W Compans
Journal:  Expert Opin Drug Deliv       Date:  2014-02-12       Impact factor: 6.648

8.  Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.

Authors:  Fu-Shi Quan; Aswani Vunnava; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

9.  Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines.

Authors:  Marc Pearton; Sang-Moo Kang; Jae-Min Song; Alexander V Anstey; Matthew Ivory; Richard W Compans; James C Birchall
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

10.  Mucosal adjuvants for influenza virus-like particle vaccine.

Authors:  Fu-Shi Quan; Eun-Ju Ko; Young-Man Kwon; Kyoung Hwan Joo; Richard W Compans; Sang-Moo Kang
Journal:  Viral Immunol       Date:  2013-11-16       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.